IL6 and type 2 diabetes mellitus: Atorvastatin was found to inhibit dihydronicotinamide-adenine dinucleotide phosphate (NADPH)-oxidase dependent reactive oxygen species (ROS) generation; however, it showed no effect on mtROS generation, and activated IL-1β and IL-6 secretion in peripheral blood mononuclear cells (PBMC) from control and type 2 diabetes (T2D) patients.